F18-rhPSMA-7, is an experimental PET indicators that is cleared quickly from the bladder, and is among the best so far. In a clinical trial, it was able to find prostate cancer metastases in 71% of men with post-prostatectomy PSA between 0.2-0.5 ng/ml, which is about 50% greater than the detection rate of the two currently approved PSMA PET indicators. See chart at end of this article:
The rapid bladder clearance means it will not be as subject to false positives in and around the prostate.
Here's the announcement. The FDA usually takes many months to grant approval, but it may be faster because there are already two indicators in this category. I expect that a fourth PSMA PET radioindicator (18F-PSMA-1007) will eventually come up for approval also.
All of the PSMA PET radioindicators have been tested in newly diagnosed patients (high risk and metastatic) and will be approved for those indications as well.